BIIB
BIOGEN INC.
- PER (TTM)
- 20.80
- PER (Forward)
- 11.67
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 1.53
- 시가총액
- 28.56B
- 배당수익률
- -
- 베타
- 0.20
- 1개월 수익률
- 9.23%
- 3개월 수익률
- -3.84%
- 6개월 수익률
- 26.08%
- 1년 수익률
- 65.05%
- 2년 수익률
- -
- 5일 평균거래량
- 724220
- 60일 평균거래량
- 1108780
- 1년 평균거래량
- 1558983
- 5d/60d 거래량 비율
- 0.65×
- 60d/1y 거래량 비율
- 0.71×
- 변동성(60일, 연환산)
- 31.16%
- BB 스퀴즈 스코어
- 1.00
- SMA50 비율
- 1.05
- SMA200 비율
- 1.17
- RSI (14)
- 59
- 20일 수렴도
- 0.03
- 52주 최고
- 201.18
- 52주 최저
- 118.17
- 고점 대비
- -3.84%
- 저점 대비
- 63.70%
펀더멘털 갱신: 2026-05-10T07:58:49+00:00 · 시세 갱신: 2026-05-10T06:12:32+00:00
회사 정보
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.